The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the most serious complications of diabetic microangiopathy. DR has an early onset and is not easy to detect. When visual impairment occurs, the optimal period for therapy is often missed. Therefore, the prevention and treatment of DR should start from the early st...

Full description

Bibliographic Details
Main Authors:	Wenjun Sha, Song Wen, Lin Chen, Bilin Xu, Tao Lei, Ligang Zhou
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	Journal of Diabetes Research
Online Access:	http://dx.doi.org/10.1155/2020/8867875

id	doaj-bf7ff8c6ebc943729ed3f994859a375b
record_format	Article
spelling	doaj-bf7ff8c6ebc943729ed3f994859a375b2020-11-25T04:10:37ZengHindawi LimitedJournal of Diabetes Research2314-67452314-67532020-01-01202010.1155/2020/88678758867875The Role of SGLT2 Inhibitor on the Treatment of Diabetic RetinopathyWenjun Sha0Song Wen1Lin Chen2Bilin Xu3Tao Lei4Ligang Zhou5Department of Endocrinology and Metabolism, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, ChinaDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaDepartment of Endocrinology and Metabolism, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, ChinaDepartment of Endocrinology and Metabolism, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, ChinaDepartment of Endocrinology and Metabolism, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, ChinaDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaDiabetic retinopathy (DR) is one of the most serious complications of diabetic microangiopathy. DR has an early onset and is not easy to detect. When visual impairment occurs, the optimal period for therapy is often missed. Therefore, the prevention and treatment of DR should start from the early stage of diabetes. Sodium-dependent glucose transporter 2 inhibitor (SGLT2i) is a new antidiabetic drug which is mainly used in clinical practice to control blood glucose of patients with type 2 diabetes prone to develop chronic heart failure. Recent studies have found that SGLT2 is also expressed in the human retina. Now, the prevention and treatment of diabetic retinopathy with SGLT2i while reducing blood sugar has become a new research field. Hence, this article reviewed the recent therapeutic and research progress of SGLT2 in the treatment of diabetic retinopathy.http://dx.doi.org/10.1155/2020/8867875
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Wenjun Sha Song Wen Lin Chen Bilin Xu Tao Lei Ligang Zhou
spellingShingle	Wenjun Sha Song Wen Lin Chen Bilin Xu Tao Lei Ligang Zhou The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy Journal of Diabetes Research
author_facet	Wenjun Sha Song Wen Lin Chen Bilin Xu Tao Lei Ligang Zhou
author_sort	Wenjun Sha
title	The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
title_short	The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
title_full	The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
title_fullStr	The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
title_full_unstemmed	The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
title_sort	role of sglt2 inhibitor on the treatment of diabetic retinopathy
publisher	Hindawi Limited
series	Journal of Diabetes Research
issn	2314-6745 2314-6753
publishDate	2020-01-01
description	Diabetic retinopathy (DR) is one of the most serious complications of diabetic microangiopathy. DR has an early onset and is not easy to detect. When visual impairment occurs, the optimal period for therapy is often missed. Therefore, the prevention and treatment of DR should start from the early stage of diabetes. Sodium-dependent glucose transporter 2 inhibitor (SGLT2i) is a new antidiabetic drug which is mainly used in clinical practice to control blood glucose of patients with type 2 diabetes prone to develop chronic heart failure. Recent studies have found that SGLT2 is also expressed in the human retina. Now, the prevention and treatment of diabetic retinopathy with SGLT2i while reducing blood sugar has become a new research field. Hence, this article reviewed the recent therapeutic and research progress of SGLT2 in the treatment of diabetic retinopathy.
url	http://dx.doi.org/10.1155/2020/8867875
work_keys_str_mv	AT wenjunsha theroleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT songwen theroleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT linchen theroleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT bilinxu theroleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT taolei theroleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT ligangzhou theroleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT wenjunsha roleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT songwen roleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT linchen roleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT bilinxu roleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT taolei roleofsglt2inhibitoronthetreatmentofdiabeticretinopathy AT ligangzhou roleofsglt2inhibitoronthetreatmentofdiabeticretinopathy
_version_	1715036995600777216

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy

Similar Items